A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02574078 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

341

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Bevacizumab
DRUG: Pemetrexed
OTHER: Best Supportive Care
DRUG: nab-Paclitaxel
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Gemcitabine
DRUG: Erlotinib
DRUG: Crizotinib
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb